Riskpilot← Back to searchSign inGet full accessNORBIOTECH AS
ASActiveOrg 911624281Odden 18B, 1397 NesøyaBusiness and other management consultancy activities · NACE 7020Est. 20130 employees
Revenue 2025
NOK 740K
-1% vs 2024
EBITDA margin
45.7%
+51% vs 2024
Equity ratio
57.6%
Financial strength
Net profit 2025
NOK 624K
+396% vs 2024
| Revenue | NOK 740K | -1% |
| EBITDA | NOK 338K | +51% |
| Net profit | NOK 624K | +396% |
| Total assets | NOK 1,2M | +73% |
| Equity | NOK 684K | +1039% |
| Employees | 0 | — |
Legal name
NORBIOTECH AS
Org number
911624281
Legal form
Aksjeselskap
NACE code
7020 · Business and other management consultancy activities
Founded
27. februar 2013
Share capital
NOK 30 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Konsulentvirksomhet rettet mot internasjonalt salg og markedsføring, videre skal selskapet investere i andre selskaper, herunder eie aksjer og andre finansielle instrumenter samt fordringer til datterselskaper, drive handel med finansielle instrumenter og annen beslektet virksomhet.
Address
Odden 18B, 1397 Nesøya
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 113 | 1 248 | 1 222 | 847 | 1 391 | 417 | 383 | 120 | 129 | 336 | 637 | 746 | 740 |
| Staff expenses | −0 | −793 | −770 | −706 | −528 | −45 | −23 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBITDA | 39 | 241 | 179 | −62 | 112 | −199 | 13 | 34 | −9 | 38 | 298 | 224 | 338 |
| Depreciation & amort. | −0 | −0 | −8 | −8 | −12 | −5 | −5 | −3 | −10 | −9 | −6 | −0 | −0 |
| EBIT | 39 | 241 | 171 | −69 | 100 | −204 | 8 | 31 | −18 | 29 | 292 | 224 | 338 |
| Net financials | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −123 | −49 | −1 | −373 | 352 |
| Profit before tax | −50 | 261 | 228 | −70 | 100 | −234 | 10 | 184 | −141 | −20 | 291 | −149 | 690 |
| Tax | 4 | 74 | 62 | −17 | −0 | 8 | 7 | −19 | −4 | 32 | 41 | 62 | 66 |
| Net profit | −54 | 187 | 166 | −53 | 100 | −243 | 3 | 203 | −137 | −52 | 251 | −210 | 624 |
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 338 | 393 | 411 | 322 | 483 | 129 | 131 | 294 | 170 | 80 | 973 | 686 | 1 187 |
| Equity | −35 | 32 | 198 | 145 | 245 | 2 | 6 | 209 | 72 | 20 | 271 | 60 | 684 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 530 | 413 |
| Short-term debt | 23 | 359 | 212 | 177 | 238 | 126 | 125 | 85 | 98 | 60 | 703 | 96 | 90 |
| Total debt | 373 | 361 | 213 | 177 | 238 | 126 | 125 | 85 | 98 | 60 | 703 | 626 | 503 |
EBITDA margin
45.7%
This company
15.8%
Market median
+189% vs market
20132025
Equity ratio
57.6%
This company
38.2%
Market median
+51% vs market
20132025
Return on equity
91.2%
This company
18.4%
Market median
+396% vs market
20132025
Net profit margin
84.3%
This company
8.1%
Market median
+941% vs market
20132025
Asset turnover
0.62×
This company
1.12×
Market median
-45% vs market
20132025
Debt / equity
0.73×
This company
0.62×
Market median
+18% vs market
20132025
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-01-01 – 2013-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
CS Deputy Member | Deputy Member | 2013 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2013 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of NORBIOTECH AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Cathrine Selmer Altepost | Deputy Member | 0 companies |
| Lucas Altepost | Chairman | 0 companies |